A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Condition: Chemotherapy-induced Nausea and Vomiting Interventions: Drug: fosnetupitant/ palonosetron; Drug: netupitant/palonosetron; Drug: dexamethasone Sponsors: Helsinn Healthcare SA; George Clinical Pty Ltd; PSI CRO AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Dexamethasone | Oral Cancer | Research | Study | Women